Name: Shift Work and Circadian Health: Real Risk, Real Mitigations
Creator: Realised
Published: 2026-06-01

Summary

Night-shift work is a genuine, dose-responsive stressor, not a verdict — the cardiovascular, metabolic, sleep-disorder and accident signals are solid enough to take seriously (and night-shift work carries a contested "probably carcinogenic" label), but the magnitudes are modest, the cohorts are confounded, the cancer call is the weakest link, and a concrete mitigation toolkit (strategic bright light during the shift, scheduled naps plus pre-shift caffeine, judicious low-dose melatonin before day-sleep, forward-rotating schedules, anchor sleep, blackout day-sleep) measurably defends the worker'

Why Strong

Strong Evidence because the entry's load-bearing claims — the existence of a real, dose-responsive cardiovascular/metabolic/accident burden, the prevalence of Shift Work Disorder, and an evidence-based mitigation toolkit with converging guideline support — rest on large prospective cohorts, dose-response meta-analyses, and clinical-practice-guideline backing. The cardiovascular dose-response, the accident/fatigue risk, and the disorder's prevalence are each independently solid.

NOT Foundational because the topic carries genuine clinical judgement, a two-sided controversy, and a contested cancer classification — not a single undisputed axiom.

NOT Moderate for the headline, because the spine is not "a few suggestive studies" — it is large prospective cohorts plus guideline-grade mitigation evidence. Only specific downstream sub-areas (the cancer-causation claim, the light-therapy magnitude) sit lower, and the entry marks them rather than inheriting their uncertainty.

The per-sub-area split (read this, not just the headline):
• Cardiovascular risk: Strong — large prospective cohorts plus dose-response meta-analysis; the most defensible hard outcome.
• Accident/fatigue risk: Strong — robust, mechanistically obvious, confirmed in on-road experiments; the least-contested harm.
• Shift Work Disorder prevalence: Strong for the disorder's existence; the ~26.5% point estimate is criterion-dependent and soft.
• Metabolic risk: Strong-to-Moderate — consistent direction, but magnitude collapses from ~2.17 to ~1.1 on adjustment, with high heterogeneity.
• Cancer causation: Moderate-to-Emerging — the IARC label is authoritative, but the underlying human evidence is "limited" and the best prospective cohorts are null. Do NOT present as settled.
• Mitigation toolkit: Strong-to-Moderate overall (guideline-backed), component-dependent — light/naps/caffeine stronger, melatonin-for-SWD and pharmacotherapy weaker; light-therapy magnitude Moderate (small N, high heterogeneity).

Practical takeaway

The framing to hold: if you must work nights, you are managing an exposure, not accepting a verdict. The levers below measurably defend your baseline — none of them is a cure, all of them help.

Defend your day-sleep (the highest-yield target).
• Make the bedroom genuinely dark — blackout blinds or a sleep mask. Daytime sleep fights a strong wake drive, so the environment has to do more work.
• Wear sunglasses on the commute home to blunt bright morning light, which would otherwise re-entrain your clock to "day" and wreck the sleep that follows. The free morning-light habit is the opposite of what a night worker wants on the way home.
• Anchor sleep: keep a consistent core sleep block even on days off where possible, so the clock has a stable phase to hold.

Use light strategically during the shift.
• Bright light at work (medium illuminance, sustained for at least an hour) improves alertness and helps your day-sleep afterward — the measured benefit is around 30 extra minutes of sleep, useful but not transformative. The hardware specifics are owned by artificial_light_vs_sunlight; route there.

Manage alertness with naps and caffeine timing.
• A nap before the shift, or a brief strategic nap during it, buys back vigilance. The nap protocol (timing, length, sleep-inertia management) is owned by napping_evidence_and_protocol.
• ~250–300 mg caffeine early in the shift supports alertness; then observe a caffeine cutoff well before your intended sleep window so it does not sabotage day-sleep.

Judicious low-dose melatonin.
• A low dose (0.5–3 mg) before day-sleep can nudge the clock and support sleep onset. This is a circadian tool, not a sedative dose. Dosing and timing specifics are owned by melatonin_dose_and_timing.

Push for better schedule design where you have any say.
• Forward (clockwise) rotation — day → evening → night — is easier on the body than backward rotation and produces better sleep and fewer complaints. This is an employer lever more than a personal one, but worth raising.

What to keep in proportion.
• The hard-outcome risks (cardiovascular, metabolic, accident) are modest per-person and partly confounded — real enough to mitigate, not a reason for fear.
• The cancer association is contested and unconfirmed in the best cohorts — do not let it drive anxiety in someone who cannot change jobs.
• Pharmacotherapy (modafinil/hypnotics) is the lowest-certainty, clearest-tradeoff lever — not first-line, and a clinician's call.

Evidence detail

Why This Entry Exists

"Night shift causes cancer" is a headline that travels faster than the evidence under it, and "shift work is fine, just push through" is the operationally convenient denial that meets it. Both are wrong in the same way: they collapse a tiered, confounded, partly-contested risk picture into a single slogan. The truth is more useful and less dramatic. Chronic circadian misalignment is a real, measurable health burden — the cardiovascular, metabolic, sleep-disorder and accident signals are robust enough to act on. But the effect magnitudes are modest, the cohorts carry heavy confounding (healthy-worker effect, socioeconomic status, smoking, obesity), and the cancer association specifically rests on limited human evidence that large prospective cohorts have failed to confirm.

So this entry is the one-stop for the shift-work question, built to be honest in both directions at once. It states the disorder and the hard-outcome risks confidently where they are well-evidenced, names the cancer claim as "probably" and contested rather than settled, and — crucially — hands the worker the evidence-based mitigation toolkit. Realised's frame is recovery, not alarm. If you must work nights, the right response is not to quit in fear or shrug in denial; it is to defend your baseline with the levers that actually work.

What bad advice this protects against, in all directions:
• "Night shift causes cancer, full stop" → overstates limited human evidence and ignores the large prospective-cohort nulls (Million Women Study, UK Biobank, EPIC-Oxford found no breast-cancer effect). The honest framing is "probably carcinogenic" (a contested classification), not settled fact.
• "Shift work is fine, just toughen up" → denies real, dose-responsive cardiovascular, metabolic, sleep-disorder and accident risk. The accident/fatigue harm in particular is the least-contested signal of all.
• "The risk numbers prove shift work will harm you personally" → the raw odds ratios (some as high as ~2x for metabolic syndrome) shrink toward ~1.1 after adjustment, exposing how much confounding inflates the headline figures. Modest, residually-confounded associations are not a personal sentence.
• "There's nothing you can do, so don't bother" → false; strategic light, naps, caffeine timing, melatonin, forward rotation and blackout day-sleep measurably reduce harm. The worker is not helpless.

This entry owns the disorder, the honestly-tiered risk picture, and the integration of the mitigation toolkit. It does not re-argue the light hardware (artificial_light_vs_sunlight), melatonin dosing specifics (melatonin_dose_and_timing), or the nap protocol (napping_evidence_and_protocol). It states those scope boundaries and defers.

Evidence

Organised by sub-area, with the tier signal inline. The headline is Strong, but the sub-areas split hard — the cancer claim is deliberately held lower than the cardiovascular and accident claims. Read the tiers, not just the thesis.

The cancer classification — authoritative label, limited underlying evidence (Strong for the label's existence; the causation claim itself is Moderate-to-Emerging).

1. IARC reaffirmed night-shift work as "probably carcinogenic to humans" (Group 2A) in 2019. A working group of 27 experts from 16 countries (IARC Monographs Volume 124, Lyon, June 2019) classified night-shift work as Group 2A, reaffirming the original 2007 call. The classification rests on limited human evidence (breast, prostate, colon, rectum), sufficient animal evidence, and strong mechanistic evidence (immunosuppression, chronic inflammation, unregulated cell proliferation). The label's authority is Strong Evidence; the underlying human-cancer evidence is explicitly only "limited," so the cancer-causation claim is Moderate-to-Emerging territory, not settled. (IARC Monographs Vol 124, Lancet Oncology 2019; iarc.who.int. Public-agency source with no product to sell — the cui bono cuts toward precaution; critics note classification-by-committee can over-weight mechanism over weak human data.)

2. The breast-cancer signal is design-dependent and likely partly artefactual. Case-control studies show elevation, but prospective cohorts are largely null. A meta-analysis of 26 studies (1,313,348 participants) found short-term night work RR 1.13 (95% CI 1.03–1.24) but long-term (≥10 years) RR 1.08 (0.99–1.17, non-significant) — the wrong direction for a true cumulative dose-response, and a strong internal signal that recall bias and confounding inflate the positive estimates. (Manouchehri E et al., BMC Women's Health 2021;21:89. Moderate Evidence — meta-analysis but heterogeneous, with the long-term null undercutting causal interpretation. No commercial conflict evident.)

3. The largest prospective cohorts found NO breast-cancer effect — the main empirical challenge to IARC. A pooled analysis of the Million Women Study (~522,000), EPIC-Oxford (~22,600) and UK Biobank (~251,000) participants found no effect of night-shift work on breast-cancer incidence. This is the cleanest null evidence available, and it runs directly against the precautionary classification. (Travis RC et al. pooled prospective analysis. Strong-to-Moderate — very large prospective samples; Cancer Research UK / academic funding with no industry incentive to downplay risk, which strengthens the null.)

Metabolic — consistent direction, magnitude collapses on adjustment (Strong-to-Moderate).

4. Shift work is associated with elevated metabolic syndrome — but the unadjusted-to-adjusted gap is the honest signal. Some pooled estimates put the odds at roughly double (OR 2.17, 95% CI 1.31–3.60 in healthcare workers, 12 studies), while other meta-analyses find modest adjusted ORs around 1.11–1.14, with high heterogeneity (I² ~82%). The wide gap between raw (~2.17) and adjusted (~1.1) estimates is itself evidence that confounding inflates the raw associations. (Sooriyaarachchi et al., Obesity Reviews 2022;13489; plus a 2021 Sleep Medicine Reviews meta with sleep/gender/shift-type moderators. Strong-to-Moderate — consistent direction, but magnitude varies widely with adjustment and I² is high. Academic.)

Cardiovascular — the most defensible hard-outcome risk (Strong Evidence).

5. Night-shift work raises cardiovascular risk in a dose-responsive way. Total CVD events RR 1.13 (95% CI 1.10–1.16), CVD mortality RR 1.27 (1.18–1.36), with each 5-year increment adding ~7% to CVD incidence and ~4% to mortality. A UK Biobank cohort of 238,661 participants corroborates. This is the most defensible hard-outcome risk in the topic — large prospective cohorts plus a dose-response meta-analysis. (Dose-response CVD meta-analysis, PMC12506678; Wang et al. UK Biobank analysis, Int J Epidemiology 2022;51(2):579. Strong Evidence. Academic/public funding; effect sizes are modest (RR ~1.1–1.3) and residual confounding (SES, smoking, BMI) cannot be fully excluded — state magnitude honestly, do not inflate.)

The disorder itself — common but criterion-dependent (Strong for prevalence; soft point estimate).

6. Shift Work Disorder affects roughly a quarter of shift workers. Pooled prevalence 26.5% (95% CI 21.0–32.8) across 29 studies, with large between-study variance driven by differing diagnostic criteria. The disorder is real and common; the exact number is criterion-dependent. (Prevalence of Shift Work Disorder systematic review/meta-analysis, PMC8021760. Strong Evidence for prevalence; the point estimate is soft. Academic, no conflict of note.)

Accident and injury — the most immediate, least-contested harm (Strong Evidence).

7. Fatigue and sleep loss sharply raise accident and injury risk. Sleep problems carry 1.62x injury risk; under 5 hours of sleep OR 2.65, 5–6 hours OR 1.79 for work injury; risk peaks after more than three consecutive night shifts; near-crash driving events are markedly elevated post-night-shift in on-road experiments. This is the most immediate harm, mechanistically obvious, and supported by both epidemiology and real-world driving studies. (Uehli K et al., "Sleep problems and work injuries: a systematic review and meta-analysis," Sleep Medicine Reviews 2014;18(1):61–73; near-crash driving study, Lee et al., PNAS 2016;113. Strong Evidence. Academic/safety-research; no commercial incentive to exaggerate.)

Mitigation: strategic bright light — measurable but modest (Moderate Evidence).

8. Strategic bright light during the night shift measurably improves day-sleep. Total sleep time +32.5 min (95% CI 21.7–43.4) and sleep efficiency +2.9% (0.80–5.02) in meta-analysis; medium illuminance (900–6000 lux) for at least an hour was most effective for total sleep time. The benefit is real but modest — about half an hour more sleep, from a small, heterogeneous pool. (Zhao et al., Scientific Reports 2025; 11 articles (10 with objective sleep measures), 195 participants total; PROSPERO CRD42024518298. Moderate Evidence — significant pooled effect but small N and high heterogeneity (TST I² 57%, SE I² 82%). Light-box vendors benefit from over-claiming — keep claims to the measured ~30 min. Defer hardware specifics to artificial_light_vs_sunlight.)

Mitigation: the multimodal toolkit — converging guideline support (Strong-to-Moderate, component-dependent).

9. A multimodal toolkit facilitates circadian adaptation and reduces Shift Work Disorder symptoms. Timed bright light at work, avoiding bright morning light on the commute home, planned naps, a pre-shift nap plus ~250–300 mg caffeine for alertness, and 0.5–3 mg melatonin before day-sleep. The AASM clinical practice guideline conditionally supports modafinil/armodafinil 30–60 min pre-shift for sleepiness (moderate certainty). Components vary in strength — light, naps and caffeine are stronger; melatonin for Shift Work Disorder specifically is weaker than for jet-lag or delayed sleep-wake phase. (Burgess bright-light/melatonin protocol; AASM Management of Shift Work Disorder CPG, GRADE-based; Cheng & Drake clinical review, PMC6859247. Strong-to-Moderate — converging guideline plus review support. Pharmacotherapy recommendations are conditional, not strong, and carry the clearest risk-benefit ambiguity — flag it. Defer melatonin dose to melatonin_dose_and_timing and nap protocol to napping_evidence_and_protocol.)

Mitigation: schedule design — a lever the worker often cannot pull (Moderate Evidence).

10. Forward (clockwise) rotation beats backward (counterclockwise) rotation. Forward rotation produces better sleep, attention, work-life balance and fewer health complaints; backward rotators have roughly double the odds of poor sleep quality. But fast-rotating mixed day/night schedules — the majority in practice — make chronotherapeutic adaptation largely infeasible, because the body never gets a stable phase to adapt to. (Forward- vs backward-rotation nurse studies, PMC8524311, PMC6164402; Cheng & Drake review noting chronotherapy is not an option on fast rotations. Moderate Evidence — consistent direction across several modest occupational studies, mostly nurses; limited RCT-grade evidence. A lever employers control, so worth surfacing even though the worker may not be able to.)

Mechanism

Why circadian misalignment is a stressor. The master clock in the suprachiasmatic nucleus is entrained primarily by light and orchestrates a cascade of peripheral clocks governing metabolism, cardiovascular tone, immune function and hormone release. Night work forces behaviour (eating, activity, wakefulness) into the biological night, while light exposure at the wrong time drags the central clock out of sync with the peripheral ones. This internal desynchrony — not "being tired" per se — is the proposed driver of the metabolic and cardiovascular signals: insulin sensitivity, blood pressure and inflammatory tone all carry a circadian rhythm, and eating or stressing the cardiovascular system at the wrong clock phase degrades the response.

Why the cancer mechanism is real but the human evidence is thin. The mechanistic case is genuine: light at night suppresses melatonin, and melatonin has oncostatic and immune-modulating roles; chronic circadian disruption is linked to immunosuppression, inflammation and unregulated cell proliferation in animal and cell models. This is why IARC rates the mechanistic evidence "strong." But a real mechanism at the bench is not the same as a demonstrated effect at the population level. The leap that fails is from "circadian disruption can promote tumour biology in models" to "night shift causes cancer in people" — the large prospective cohorts that should show it largely do not. The mechanism being real is not proof that your shift is giving you cancer.

Why fatigue harm is the cleanest signal. The accident and injury risk needs no contested epidemiology: sleep loss and circadian misalignment degrade vigilance, reaction time and decision-making in a directly measurable, dose-responsive way, and the effect compounds across consecutive nights. This is mechanistically obvious and confirmed in on-road driving experiments, which is exactly why it is the least-disputed harm in the whole topic.

Why the mitigations work. The toolkit attacks the misalignment from both ends. Bright light during the shift props up alertness and helps shift the clock; avoiding bright morning light on the commute home stops the clock being re-entrained to "day," protecting day-sleep. Naps and pre-shift caffeine buy back the vigilance lost to sleep debt. Low-dose melatonin before day-sleep nudges the clock and supports sleep onset against a daytime drive. Forward rotation works with the clock's natural tendency to drift later, which is easier to follow than forcing it earlier. None of this restores a day-worker's physiology, but each lever measurably narrows the gap.

Risks And Contraindications

• Fear-mongering the cancer claim is the central hazard. "Night shift causes cancer" overstates limited human evidence and ignores the large prospective-cohort nulls. For someone who cannot change jobs, this is anxiety-inducing misinformation, not a useful warning. Frame it as "probably" (the contested IARC 2A classification), name the cohort nulls, and never present it as settled.
• Confounding-blindness inflates personal risk. The cardiovascular and metabolic odds ratios (~1.1–2.2) are real, but the gap between unadjusted and adjusted estimates exposes heavy confounding (socioeconomic status, smoking, BMI, the healthy-worker effect). Presenting raw odds ratios as causal personal effect sizes overstates the threat.
• Mitigation over-promise. Light therapy's measured benefit is about 30 extra minutes of sleep, from a small (N=195), high-heterogeneity meta-analysis — a help, not a cure. Pharmacotherapy carries the weakest risk-benefit and should never be presented as first-line.
• Caffeine and melatonin timing matters. Caffeine too late in the shift sabotages the very day-sleep the worker is trying to protect; melatonin is a low-dose circadian nudge, not a sedative — getting the dose or timing wrong wastes it. Defer the specifics to the owning entries rather than improvising.
• Pharmacotherapy is a clinician's decision. Modafinil, armodafinil and hypnotics carry their own risk profiles and are conditionally (not strongly) recommended — flag the ambiguity and route to a clinician.

Controversy

Nature: a genuine, dose-responsive health burden (cardiovascular, metabolic, sleep-disorder, accident risk) entangled with a contested cancer classification and a tug-of-war between precautionary public-health bodies and large neutral cohorts that found nothing — with an operationally-convenient denial pulling from the other side. Error sits at both poles: the doom version oversells the cancer claim, and the dismissal version denies the real hard-outcome and accident risks.

Position A — "Night-shift work and circadian misalignment are genuinely harmful." The precautionary take.
• Best evidence: real and largely solid. IARC's Group 2A classification (27 experts, 16 countries) reaffirms a "probably carcinogenic" call; shift workers show consistently elevated cardiovascular risk (total CVD events RR 1.13, CVD mortality RR 1.27, dose-responsive), roughly doubled metabolic-syndrome odds in some pooled estimates, ~26.5% Shift Work Disorder prevalence, and steep fatigue-driven accident risk. This is a measurable burden, not a lifestyle quibble.
• Where it overshoots: the cancer call rests on limited human evidence, strong only in animals and mechanism. Treating "probably carcinogenic" as "causes cancer" borrows the cardiovascular/accident credibility to prop up the weakest link.

Position B — "The risk is real but smaller and shakier than headlines imply, and the cancer call is the weakest link." The skeptical take.
• Best evidence: the cancer signal splits hard by design. Case-control studies show elevation but prospective cohorts are largely null — short-term RR 1.13, but long-term ≥10-year RR 1.08 (non-significant), the wrong direction for a true dose-response. The 1.3-million-participant Million Women Study, EPIC-Oxford and UK Biobank pooled analysis found no breast-cancer effect. Cohorts are heavily confounded (healthy-worker effect, SES, smoking, obesity, crude shift definitions), and the cardiovascular/metabolic relative risks, while consistent, are modest and residually confounded.
• Where it overshoots: "smaller and shakier" can slide into "not real," which denies the genuine cardiovascular, metabolic, sleep-disorder and accident signals — the last of which is barely contested at all.

The funding/bias dimension — cui bono, both ways. The precaution side (IARC/WHO, academic occupational-health researchers) has no product to sell, but classification-by-committee and the publish-a-positive-finding incentive can over-weight mechanism and case-control signals over weak or null cohort data, and advocacy for shift-work compensation creates an incentive to keep the 2A label. The product side (light-therapy and blue-blocker vendors, melatonin and modafinil/armodafinil manufacturers, wearable and sleep-app companies) profits from amplifying both the threat and the efficacy of the fix. The employer side (industries dependent on 24/7 labour) has an interest in downplaying harm and resisting schedule reform. No camp is clean.

Realised Position: Both A and B are true, and the worker deserves the levers, not the fear. Night-shift work is a genuine, dose-responsive stressor — the cardiovascular, metabolic, sleep-disorder and accident signals are solid enough to take seriously, which is why this is a Strong-Evidence topic. The cancer association is real-but-contested: state it honestly as "probably" with the prospective-cohort nulls named, never as fact. And the load-bearing job is to hand over the mitigation toolkit — strategic light, naps plus caffeine, judicious melatonin, forward rotation, anchor sleep, blackout day-sleep — quoted at its measured effect sizes. The frame is recovery: if you must work nights, here is how to defend your baseline. That this conclusion sells no product and demands no panic is the tell that it is tracking the evidence.

Cross-Pillar Connections

This is a genuinely cross-pillar topic — circadian disruption (sleep) drives cardiovascular and metabolic risk (physical) and degrades vigilance and mood (mental).
• Sleep (circadian_rhythm_optimization): the circadian umbrella this entry sits under; shift work is the canonical chronic-misalignment stressor.
• Cross-pillar (artificial_light_vs_sunlight): owns the light hardware and the artificial-versus-natural comparison; this entry uses strategic light as a mitigation and defers the specifics there.
• Sleep (melatonin_dose_and_timing): owns melatonin dosing and timing; this entry recommends low-dose melatonin before day-sleep and routes there for the how.
• Sleep (napping_evidence_and_protocol): owns the nap protocol; this entry uses pre-shift and strategic naps and defers the timing/length specifics there.
• Cross-pillar (chronic_disease_risk_mitigation): owns the broader cardiovascular and metabolic risk-mitigation story this entry's hard-outcome signals feed into.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• We'd downgrade the cancer component (toward not asserting causation at all) if a new IARC re-evaluation or a large pooled prospective analysis — beyond Million Women and UK Biobank — moved the human evidence from "limited" to "inadequate," or if the case-control-versus-cohort split were definitively shown to be fully explained by recall and selection bias.
• We'd upgrade the overall topic toward firmer causation if an RCT-grade or Mendelian-randomization study isolated circadian misalignment from socioeconomic and lifestyle confounders and still showed the cardiovascular/metabolic effect. Some chronotype Mendelian-randomization work is emerging here.
• We'd strengthen the mitigation toolkit if a large, low-heterogeneity RCT showed the bright-light / nap / melatonin bundle reduces hard outcomes (not just sleep minutes).
• We'd soften the mitigation promises if a well-powered trial showed forward-versus-backward rotation makes no real-world health difference, or that workplace light therapy fails to replicate the +32-minute total-sleep-time benefit at scale.
• What would NOT move us: the accident/fatigue risk (mechanistically obvious, confirmed on-road), the existence of a real cardiovascular and metabolic signal (consistent across large cohorts), or the framing commitment itself — state magnitudes honestly, name the contested cancer status, and always hand the worker the levers.

Industry bias note

Structural incentives the evidence base may reflect

Cui bono runs in both directions, and no camp is clean — which is why the large neutral cohorts and the independent guideline bodies are the anchors.
• The precaution end: IARC/WHO and academic occupational-health researchers have no product to sell, and that cuts toward trustworthy precaution. But classification-by-committee and the publish-a-positive-finding incentive can over-weight mechanism and case-control signals over weak or null cohort data, and advocacy for shift-work compensation (some countries treat night-shift breast cancer as occupational) creates a standing incentive to keep the 2A label.
• The product end: light-therapy and blue-light-glasses vendors, melatonin and modafinil/armodafinil manufacturers, and wearable/sleep-app companies all profit from amplifying both the threat and the efficacy of their fix. Light-box marketing routinely cites the optimistic end of a small, heterogeneous evidence base — which is exactly why the measured ~30-minute figure, not the marketed one, is the honest number to quote.
• The employer end: industries dependent on 24/7 labour have an interest in downplaying harm and resisting schedule reform, which can bias employer-funded or operationally-convenient "fast rotation is fine" framing.
• The clean signal: the hard-outcome cardiovascular, metabolic and accident risks are funded mostly by neutral public/academic money and survive statistical adjustment, so they are trustworthy at modest magnitude. The cancer claim sits in a tug-of-war between precautionary public-health bodies and large neutral cohorts that found nothing. The mitigation claims should be quoted at their measured, not marketed, effect sizes. Realised's position — take the real risks seriously, name the contested ones honestly, hand over free behavioural levers — benefits no seller, which is the tell that it tracks the evidence.

Shift Work and Circadian Health: Real Risk, Real Mitigations